America Great Health, Inc.

Overview

America Great Health, Inc., formerly Crown Marketing, is a Wyoming corporation. Since a change of control in January 2017, the company has operated as an investment and holding vehicle focused on health-related technologies and businesses. Core strategic areas include protein and peptide drug research and development, diagnostics and medical devices with AI and cloud computing, cell therapy, regenerative medicine, and supplements manufacturing and sales. The company operates across the United States, China, and Australia through subsidiaries and joint ventures.

Corporate structure and key subsidiaries

• GOF Biotechnologies Inc. (formed November 2021)
  • America Great Health owns 75%; Men Hwei Tsai (Tsai) owns 25%.
  • The company has provided advisory support for GOF’s drug development and regulatory efforts (oral insulin and Amylase X), including a consulting arrangement with Dr. Kevin Buckman.
• Nutrature Health LLC (formed November 4, 2021) — 100% owned.
• International Institute of Great Health, Inc. (IIGH) — California (formed February 4, 2021)
  • Research institute connecting medical and technical experts across regions in biomedicine, clinical medicine, health IT, AI, data analysis, and software development.
• Meizhong Health Industry Development Co., Ltd. — China (formed June 24, 2019)
  • Focused on M&A, investments, financings, and marketing of medical equipment and health products in China.
• Sijinsai (Hainan) Biological Tech Ltd. — China (formed June 2021)
  • Joint venture in Hainan for stem cell-related R&D, production, sales, materials procurement, M&A, and consulting services.
• Purecell Group — Australia
  • 51% equity interest acquired via cooperation agreement dated June 30, 2020; acquisition completed in May 2021. Purecell remains autonomous in day-to-day operations.
• Joint venture with Brilliant Healthcare Limited — China
  • Cooperation agreement signed December 7, 2020. The planned JV in China targets stem cell and related activities. The company intends to invest US$4.2 million within 24 months for a 60% ownership stake; Brilliant contributes patented technology for a 40% stake.
• Issuance of 510,000,000 shares to Purecell’s trustee occurred April 6, 2021 as part of the Purecell acquisition mechanism.

Notable transactions and collaborations

• 2020–2021: Acquisition of 51% equity in Purecell Group (completed May 2021).
• 2020–2021: Cooperation with Brilliant for a China JV (Sijinsai Hainan) with a planned 60/40 equity split contingent on company investment.
• 2021: Formation of GOF Biotechnologies Inc., including leadership and advisory arrangements.
• 2021: Issuance of warrants to Dr. Kevin Buckman, MD, under an Advisory Committee consulting agreement — 500,000 shares at $0.01 per share, plus additional warrants tied to development milestones (IND, Phase I/II/III, and license transfer milestones).

Operations and staffing

• Five full-time employees as of the report date.
• The company uses outside consultants and contractors for non-policy-making activities, including marketing and administrative functions.

Properties and facilities

• Los Angeles County, CA: Month-to-month lease with GKT, Alhambra, LP; current rent including management fee is $4,939.17 per month.
• Irwindale, CA: Operating lease with SoCal Industrial LLC; term June 1, 2024 to May 31, 2026; monthly rent including management fee is $1,940.40.

Geographic footprint

• United States — headquartered in Wyoming; U.S. subsidiaries include IIGH in California.
• China — Sijinsai Hainan JV and Meizhong Health Industry Development.
• Australia — Purecell Group investment.
• Strategic partnerships in China with Brilliant Healthcare Limited focused on stem cell technology and related activities.

Investments and equity positions

• Purecell: 51% equity acquired (completed May 2021).
• Brilliant JV: Planned 60% ownership by America Great Health following a US$4.2 million investment within 24 months; Brilliant to hold 40% via contribution of patented technology.
• GOF Biotechnologies: America Great Health holds 75%; Tsai holds 25%.
• Documented initial investment activity includes a $50,000 payment on July 9, 2021 related to JV activity.
• 510,000,000 shares issued to Purecell’s trustee on April 6, 2021 as part of the acquisition mechanism.

Legal and regulatory status

• The company reports no threatened or pending legal proceedings against the company or its officers and directors.
• America Great Health is designated as a “smaller reporting company” under Exchange Act Rule 12b-2.

Summary

America Great Health is a health-focused investment and holding company with a multi-entity structure across the U.S., China, and Australia. It pursues M&A, investments, and development in health technologies, including stem cell research, peptide and protein drugs, diagnostics, and AI-enabled devices. Key transactions include a majority stake in Purecell and planned JV activity with Brilliant in China. The company maintains a small core staff, uses consultants for operational support, and operates from leased offices in California.